Amicus Therapeutics (FOLD) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
May 9, 2017 7:30 AM EDTÂ Â 100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU
On Target to Reach 300 Patients on Galafold by Year-End 2017
Additional Important Phase 1/2 Pompe Clinical Data Expected in 2Q17 and 3Q17
Phase 3 EB Topline Data on Track for 3Q17
CRANBURY, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced... More
